Deeper questions on the CJC-1295 & Ipamorelin research blend — laboratory context only.
Is this the DAC or no-DAC version of CJC-1295?
V8's blend uses CJC-1295 without DAC (no Drug Affinity Complex). The no-DAC form has a shorter research half-life than the DAC-modified version, which is a meaningful distinction in the literature since the two are often conflated under the same name.
Why pair a GHRH analog with a ghrelin-mimetic?
The two act on separate receptor pathways that converge on GH release — CJC-1295 mimics growth-hormone-releasing hormone (GHRH), while Ipamorelin mimics ghrelin at the GH secretagogue receptor. Literature on paired secretagogues describes an amplified, more pulsatile release pattern than either compound studied alone — see growth hormone research.
What makes Ipamorelin different from older GH secretagogues like GHRP-6?
Selectivity. Ipamorelin is reported in the literature as substantially more selective for GH release, with markedly less impact on cortisol, prolactin, and ACTH compared to earlier-generation secretagogues — a frequently cited reason it largely superseded GHRP-6 in research use.
How is the blend supplied and stored?
As a co-lyophilized powder, kept cold and dark; general handling follows reconstitution and storage.
How is quality documented?
Each peptide component is independently verified by HPLC purity and mass spec, consolidated into one batch certificate of analysis — see purity testing.
Are the two peptides structurally related?
No — different mechanisms and different sequences entirely (a modified GHRH fragment vs. a synthetic pentapeptide). See CJC-1295 vs Ipamorelin for the side-by-side structural comparison.
Product page: CJC-1295 (no-DAC) + Ipamorelin research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.